Protein & Peptide Medications Await Promising Future, Reports GBI Research

20 Jul 2012 • by Natalie Aster

Since being recognised in the 1950’s, many protein and peptide based therapeutics have been discovered. However, it is only over the last decade that developments have really drawn the attention of the pharmaceutical industry, states a new report by healthcare experts GBI Research.

According to the report, "Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development" by GBI Research there are currently 280 protein and peptide-based therapeutics molecules (excluding antibodies) currently being marketed for the treatment of a huge variety of diseases, ranging from cancer to HIV and hepatitis. This group of products is approved for the treatment of 283 indications across 22 therapeutic areas.

Report Details:

Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
Published: July, 2012
Pages: 44
Price: US$ 3.500,00

This total, however, may witness a boom in coming years, as GBI Research has identified 571 molecules in the discovery, preclinical and clinical stages of development. Even this considerable figure is likely to be an underestimate as companies do not always disclose this information. These recorded compounds exist in 953 indication-specific developmental programs, and 629 programs are currently in clinical development.

These therapy types are highly promising as they exert a high level of specificity on their respective targets, which can make them much more effective than traditional treatments. Their potential is increased by their high safety profiles and the high level of tolerance that patients exhibit to their application.

Protein and peptide therapies are not without their disadvantages, however, the size of these molecules poses substantial challenges as it can adversely affect intestinal uptake when the medication is administered orally. There are also issues regarding their half-life values and stability, with their tendency to be quickly hydrolyzed by plasma enzymes.

More information can be found in the report “Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development” by GBI Research.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970